Story thread · 2 reports / 2 sources

Arcturus reports phase 2 data for OTC deficiency treatment

investing.com · 7h · first report

The coverage

  1. Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency

    seekingalpha.com · 5h

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.